
Lives on the Line: Komen® Speaks Out Against Reconciliation Bill as Millions Stand to Lose Coverage
For breast cancer patients and survivors, insurance coverage through Medicaid and the Affordable Care Act (ACA) Marketplaces is not a luxury; it is a lifeline. In the U.S., more than 72 million people rely on Medicaid. In fact, 1 in 10 adults with a history of cancer utilize Medicaid for insurance coverage. Millions of others rely on plans offered through the ACA Marketplaces. This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced, outcomes are worse and is expensive to treat.
"The One Big Beautiful Bill Act includes changes that raise serious concerns for the breast cancer community,' said Paula Schneider, Komen president and CEO. 'Access to affordable, timely health care is critical — not only for those newly diagnosed, but also for those living with and beyond breast cancer. Policies that make it harder to secure coverage or navigate the system risk delaying care when every day counts. We urge our leaders to do better for the breast cancer community who depend on timely, affordable care."
The bill will implement harsh work reporting requirements that would restrict access to quality and affordable healthcare for millions of patients falling between the gaps. Even with exemptions for those with serious illnesses, it remains unclear whether breast cancer patients would be required to navigate through administrative red tape to demonstrate their qualification. These patients already face an incredible burden of navigating our health care system on top of their medical care. The last thing a person undergoing cancer treatment needs is more paperwork, deadlines, and red tape every six months.
Additional policies included in the bill make several harmful changes to ACA Marketplace plans which erodes coverage for millions of Americans, including breast cancer patients and survivors.
These damaging policies come at a time when access to care is at its most vulnerable. Proposals to eliminate funding for the National Breast and Cervical Cancer Early Detection Program —a vital state-federal partnership which aims to increase early detection among women with low-incomes — combined with Congress' failure thus far to renew important health care tax credits would leave countless with nowhere to turn. Now that the One Big Beautiful Bill Act has passed, Congress must prioritize renewing the health care tax credits that help millions access coverage and fight against proposals to implement draconian cuts to NBCCEDP that further erode public health infrastructure.
Komen urges Congress to do better for the breast cancer community and will continue to pursue policies that reverse or mitigate the damage done to patients through this legislation.
Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
3 hours ago
- Newsweek
Republican Unloads Medicaid-Related Stock Before Voting For Trump Tax Bill
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Republican Congressman sold a Medicaid-related stock before voting for President Donald Trump's massive tax and spending package, which affects Medicaid. In May, Pennsylvania Representative Robert Bresnahan sold stocks in Centene Corporation, a healthcare company that works as an intermediary for government and private healthcare programs, while debates about the tax package, called the "One Big, Beautiful Bill," continued. The trade has recently been made publicly available. Newsweek contacted representatives for Bresnahan by email outside of business hours to comment on this story. Why It Matters The House of Representatives on Thursday passed the "One Big, Beautiful Bill" 218 votes to 214 after months of internal GOP divisions and last-minute negotiations. UNITED STATES - NOVEMBER 15: Rep.-elect Robert Bresnahan, R-Pa., poses for a photo on the House steps after freshman members of Congress posed for their class photo on the House steps of the Capitol on... UNITED STATES - NOVEMBER 15: Rep.-elect Robert Bresnahan, R-Pa., poses for a photo on the House steps after freshman members of Congress posed for their class photo on the House steps of the Capitol on Friday, November 15, 2024. More Bill Clark/CQ Roll Call via AP Images The legislation extends Trump's 2017 tax cuts, eliminates taxes on tips and overtime, and boosts funding for immigration enforcement and defense. The bill will also reduce Department of Health and Human Services budget by $880 billion over 10 years, which would include cuts to Medicaid alongside other measures such as implementing work requirements. The CBO estimates that the bill would result in 11.8 million people losing health insurance by 2034, with the majority of those people losing coverage from Medicaid. Meanwhile, members of Congress are allowed to buy and sell stocks, but the practice has attracted bipartisan criticism because of concerns it may facilitate insider trading, if lawmakers are privy to information about assets that could move markets. There are also concerns politicians with stock holdings can influence the assets they hold to inflate their share value. What To Know According to his financial disclosures, Bresnahan purchased between $1,001 and $15,000 in Centene Corporation on April 8. On May 15, he sold those stocks. This came a week before the legislation initially passed in the House. In July, it was reported that shares in the company fell almost 40 percent after the insurer predicted its 2025 revenues would be hit. The disclosures were first reported by data platform Quiver Quantitative, which claimed Bresnahan does not manage his own stock portfolio and plans to set up a blind trust. What People Are Saying Speaking to Newsweek, Veljko Fotak, a finance professor at the University at Buffalo in New York, said the trade "definitely is not appropriate." "It does suggest he thought the value of the shares would tank. His position allowed him to be a better judge of that probability than you or I. He did not have clear foresight—but he did have an unfair advantage, compared to other traders. "I will also say – the moral optics are made worse by the nature of the event. Profiting from inside information regarding the likelihood of legislation passing is ugly enough—when that inside information is about millions of individuals losing access to Medicare, the optics are somehow even worse.... This is Nero selling lumber while Rome is burning." On X, New Mexico Democrat Melanie Stansbury wrote: "This Congressman literally dumped stock in a Medicaid provider company right before this bill came to the Floor. Don't be fooled—these guys know exactly what they're doing." Elizabeth Warren, a Democratic Senator from Massachusetts, wrote: "Protecting his stock portfolio while ripping away health care from 17 million Americans This is Washington at its worst. We need to ban Congressional stock trading."


Washington Post
4 hours ago
- Washington Post
Why the GOP's Medicaid cuts are less than meets the eye
Criticism of the just-passed Republican budget bill has focused on its supposedly 'deep cuts' to Medicaid. House Minority Leader Hakeem Jeffries warned: 'Children will be hurt. Families will be hurt. Women will be hurt. Seniors will be hurt. Everyday Americans with disabilities will be hurt.' The Congressional Budget Office projects that in 2034, 11.8 million fewer Americans will have Medicaid coverage because of the bill — a figure that has been cited more than any other in Democratic rhetoric.


Associated Press
5 hours ago
- Associated Press
R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry
DUBLIN--(BUSINESS WIRE)--Jul 4, 2025-- The 'Immunomodulator Therapeutics Market, Global, 2024-2030" report has been added to offering. Revenue estimate for the base year 2024 is $93 billion with a CAGR of 9.0% for the study period 2024-2030. This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting or suppressing them. It categorizes the market by modality and key indications, providing a 6-year revenue forecast for global immunomodulator prescription drugs, alongside an analysis of key industry participants. The geographic scope encompasses North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and Latin America (LATAM), with regional revenue share estimates presented on a best-effort basis. The report also discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for immunomodulator therapies, and offers competitive assessments and revenue share analyses. It examines the factors driving and restraining growth in this space, offering insights into drug development trends, partnerships, and the investment landscape. The report highlights key companies pioneering disruptive virtual care technologies and adjunctive therapies for effective disease management. Based on clinical needs, technological advancements, business models, and competitive dynamics, the report identifies the growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2024, and the forecast period is from 2025 to 2030. Growth Drivers Rising Prevalence of Autoimmune and Inflammatory Diseases Increasing prevalence of diseases like lupus, RA, Crohn's disease, and psoriasis is driving demand for immunomodulators like tumor necrosis factor (TNF) inhibitors (e.g., Humira, Remicade) and JAK inhibitors (e.g., Xeljanz). The rapidly aging global population is more susceptible to chronic autoimmune conditions. It is further bolstering demand for treatments tailored to older adults, such as more tolerable biologics. Biotech Advancements Innovations in biotech platforms and advanced modalities such as CGT, bispecific antibodies, and RNA therapies are enhancing the efficacy and safety profiles of immunomodulators and driving the development of next-gen targeted therapies. Carisma Therapeutics Inc. and Moderna, Inc. have collaborated to use Carisma's proprietary CAR-M technology and Moderna's mRNA/lipid nanoparticles (LNP) platform to develop a macrophage engineering approach for autoimmune diseases. Growing Investment in R&D Increased funding from both public and private sectors is accelerating R&D efforts for discovering new therapies and improving existing ones. The NIH allocates significant funding for research on immunomodulatory therapies, fostering innovation. An increasing number of M&A deals demonstrate a growing focus on immunology by big pharma. Success in Oncology and Expanding Applications The success of immunotherapies in oncology has raised awareness and acceptance of similar approaches in treating autoimmune and inflammatory diseases. For example, Roche's Gazyva/Gazyvaro (obinutuzumab), approved in 100 nations for several lymphoma types, is being investigated in the Phase III REGISTRY trial for lupus nephritis. Growth Restraints Immunomodulator Therapeutics: Growth Restraints, Global, 2025-2030 Stringent Regulatory Processes: Stringent regulatory processes for immunomodulatory treatment approval or the development of novel mechanisms of action, globally, can cause delays in market access and raise development expenses for pharmaceutical companies. Moreover, inadequate reimbursement/insurance coverage globally may deter wide-scale adoption, especially in public health systems or regions with limited healthcare resources. Inadequate coverage of high-cost new drugs would increase the expenses of managing long-term conditions, impacting patient compliance and market growth. Potential Adverse Effects and Safety Concerns: Immunomodulators may have serious adverse effects, such as an elevated risk of infections and autoimmune responses. For example, checkpoint inhibitor use in autoimmune disease is linked to immune-related side effects that need to be carefully managed. Adverse outcomes and safety risks may lead to regulatory actions such as market recalls, limited prescriptions, and reduced patient confidence, challenging market uptake. Patent Expiry: Expiry of blockbuster drug patents is leading to the introduction of biosimilars and generic versions, intensifying market competition, resulting in price erosions, and leading to a loss of sales revenue for branded products. For example, AbbVie's blockbuster Humira, approved for several autoimmune conditions like RA, psoriasis, Crohn's disease, and ankylosing spondylitis, started facing biosimilar competition in 2023. Patient Inconvenience: Biotech advancements have facilitated the development of effective biologic therapies; however, therapy administration requires frequent injections or infusions, making it challenging for patients to adhere to their treatment regimens. It may affect overall patient satisfaction and treatment discontinuation. The Impact of the Top 3 Strategic Imperatives on the Immunomodulator Therapeutics Industry Disruptive Technologies Why: There is an increasing incidence of autoimmune diseases, particularly impacting women. Limitations in existing therapies demand more targeted applications. Analyst Perspective: A new wave of drug classes (JAK1, IL, calcineurin, TNF?, TYK2, PDE4), across small molecules, biologics, and cell and gene therapies, will emerge, offering enhanced efficacy and safety profiles for treating autoimmune and inflammatory conditions. There will be a growing trend towards combination therapies that utilize multiple mechanisms of action to achieve better clinical outcomes. Internal Challenges Why: The industry is moving toward an extended patent cliff, with several revenue-generating blockbuster drugs like Humira and Stelara losing their exclusivity, leading to revenue losses and increased biosimilar competition, creating an urgent need for pipeline growth, and driving increased research and development (R&D). Resource demands for R&D can strain budgets, especially for smaller biotech firms. Analyst Perspective: Companies may increasingly seek strategic partnerships to share costs and risks, fostering innovation through collaborative R&D efforts. Companies that emphasize unique value propositions in these strategic alliances will be better positioned to access markets/fair pricing with drugs like JAK inhibitors and women-specific therapies. Payers will scrutinize clinical costs and patient outcomes to ensure balance and sustainable reimbursement models that reflect indication-specific needs and improve affordability. Transformative Megatrends Why: Healthcare systems are under pressure to contain current and future spending. Healthcare plan sponsors are considering their next moves as governments contemplate the impact of the Inflation Reduction Act (IRA) 2022, and associated price cuts in the United States. Analyst Perspective: Firms will invest in adaptive trial designs for evidence generation to expedite approvals for novel MoA-based targeted therapies, advancing precision medicine going forward. Pharma companies will utilize diagnostic delivery services to improve patient access by partnering with telehealth/AI-enabled symptom monitoring platforms (e.g., Ada Health) and focus on an emerging market-expansion strategy. Focus on predictive convergence of drugs and digital therapeutics will likely personalize medicine and improve experiences and outcomes. Scope of Analysis Ecosystem in the Immunomodulator Therapeutics Sector Growth Opportunity Universe in Immunomodulator Therapeutics Sector Key Competitors For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/04/2025 06:43 AM/DISC: 07/04/2025 06:43 AM